{'52WeekChange': -0.69398093,
 'SandP52WeekChange': None,
 'address1': '100 South Saunders Road',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.01,
 'askSize': 1800,
 'averageDailyVolume10Day': 1012887,
 'averageVolume': 1493244,
 'averageVolume10days': 1012887,
 'beta': 2.204481,
 'beta3Year': None,
 'bid': 0.9646,
 'bidSize': 1800,
 'bookValue': 1.033,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lake Forest',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.02,
 'dayLow': 0.9501,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 0.569,
 'enterpriseToRevenue': 0.182,
 'enterpriseValue': 35334076,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '510 744 8001',
 'fiftyDayAverage': 0.8882857,
 'fiftyTwoWeekHigh': 3.55,
 'fiftyTwoWeekLow': 0.55,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 61332394,
 'forwardEps': 0.15,
 'forwardPE': 6.6666665,
 'fromCurrency': None,
 'fullTimeEmployees': 125,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01517,
 'heldPercentInstitutions': 0.79632,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/assertiotx.com',
 'longBusinessSummary': 'Assertio Holdings, Inc., a specialty pharmaceutical '
                        'company, provides medicines in neurology, orphan, and '
                        'specialty areas in the United States. The company '
                        'offers Gralise (gabapentin), a once daily product for '
                        'the management of postherpetic neuralgia; CAMBIA '
                        '(diclofenac potassium for oral solution), a '
                        'non-steroidal anti-inflammatory drug for the acute '
                        'treatment of migraine attacks; and Zipsor (diclofenac '
                        'potassium liquid filled capsules), a non-steroidal '
                        'anti-inflammatory drug for treating mild to moderate '
                        'acute pain. It also provides NUCYNTA ER (tapentadol '
                        'extended release tablet), a product for the '
                        'management of pain severe enough to require daily, '
                        'around-the-clock, and long term opioid treatment, '
                        'including neuropathic pain related to diabetic '
                        'peripheral neuropathy in adults; and NUCYNTA IR '
                        '(tapentadol), a product for the management of '
                        'moderate to severe acute pain in adults. In addition, '
                        'the company offers long-acting cosyntropin, an '
                        'alcohol-free formulation of synthetic '
                        'adrenocorticotropic hormone. Assertio Therapeutics, '
                        'Inc. has a collaboration and license agreement with '
                        'Ironwood Pharmaceuticals, Inc. The company was '
                        'formerly known as Assertio Therapeutics, Inc. and '
                        'changed its name to Assertio Holdings, Inc. in May '
                        '2020. Assertio Holdings, Inc. was founded in 1995 and '
                        'is headquartered in Lake Forest, Illinois.',
 'longName': 'Assertio Holdings, Inc.',
 'market': 'us_market',
 'marketCap': 105405000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_363049',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -161670000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.9646,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.35,
 'phone': '224 419 7106',
 'previousClose': 0.9609,
 'priceHint': 4,
 'priceToBook': 0.96805423,
 'priceToSalesTrailing12Months': 0.5429665,
 'profitMargins': -0.8328,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.02,
 'regularMarketDayLow': 0.9501,
 'regularMarketOpen': 0.9646,
 'regularMarketPreviousClose': 0.9609,
 'regularMarketPrice': 0.9646,
 'regularMarketVolume': 615360,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 105355000,
 'sharesPercentSharesOut': 0.0163,
 'sharesShort': 1721064,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2187562,
 'shortName': 'Assertio Holdings, Inc.',
 'shortPercentOfFloat': 0.0165,
 'shortRatio': 1.04,
 'startDate': None,
 'state': 'IL',
 'strikePrice': None,
 'symbol': 'ASRT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.234,
 'twoHundredDayAverage': 0.94330937,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b0b71d5e-e500-3f56-bb27-7703d923929a',
 'volume': 615360,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.assertiotx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '60045'}